Aptamer-based impedimetric determination of the human blood clotting factor IX in serum using an interdigitated electrode modified with a ZnO nanolayer
- 298 Downloads
This article describes a sensitive impedimetric method for the determination of human blood coagulation factor IX protein (FIX) which is present in extremely low concentration in serum. An interdigitated electrode (IDE) whose surface was layered with zinc oxide was modified with two kinds of probes. One is an antibody, the other an aptamer against FIX. A comparative study between anti-FIX aptamer and anti-FIX antibody showed the aptamer to possess higher affinity for FIX. A sandwich aptamer assay was worked out by using the FIX-binding aptamer on the surface of the IDE. It has a detection limit as low as 10 pM which makes it 4 to 30-fold more sensitive than any other method reported for FIX. Moreover, to practice detection in clinical samples, FIX was detected from the human blood serum by spiking. In our perception, the sensitivity of the ZnO-modified IDE presented here makes it a promising tool for sensing clinically relevant analytes that are present in very low (sub-pM) concentrations.
KeywordsCoagulation Hemophilia Impedance Resistance analysis Factor IX Aptamer Monoclonal antibody Clotting
Y. Chen thanks the support from High Impact Research grants - “MoE Grant UM.C/625/1/HIR/MOE/DENT/09” and “UM-MoHE HIR UM.C/625/1/HIR/MOHE/MED/16/5”
Compliance with ethical standards
The author(s) declare that they have no competing interests.
- 7.Busher JT (1990) Serum albumin and globulin. Clin Methods Hist Phys Lab Exam 497–499Google Scholar
- 30.Gopinath SCB, Perumal V, Kumaresan R et al (2016) Nanogapped dielectric impedance surface for sensitive detection of Mycobacterium tuberculosis 16 kDa antigen. Microchim ActaGoogle Scholar
- 34.Povsic TJ, Vavalle JP, Aberle LH et al (2013) A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial. Eur Heart J 34:2481–2489. doi: 10.1093/eurheartj/ehs232 CrossRefGoogle Scholar